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Background: Discovery of the molecular pathogenesis of Gastrointestinal stromal tumors led to the
development of targeted therapies, revolutionizing their treatment. However, surgery is still the main-
stay of GIST therapy and the only chance for cure.
Aim: Here we present a single institutional consecutive case series of 159 GIST-patients.
Methods and patients: A total of 159 GIST-patients who underwent resection between 1994 and 2011
were reviewed for clinicopathohistological data, informations on surgical and medical therapy and
further follow-up, outcome and survival data.
Results: Laparoscopic (25.2%) and open (71.1%) GIST surgery achieved complete resection rates of 97.5%
and 85.2%, whereas 44.4% of incomplete and 6.6% of complete resected patients died from GIST.
Compared to open surgery laparoscopy signiﬁcantly reduced duration of operation (183.4 vs. 130.6 min),
length of hospitalization (16.1 vs. 8.3 d) and morbidity (23% vs. 7.5%). Mean survival time was 3.7  2.7
years (R0: 5.1 a and R1: 2.6 a) and the mean overall survival was 4.5  3.8 years.
Conclusion: Complete surgical resection is the primary goal and laparoscopy can be performed safely in a
subset of GIST-patients with potential perioperative advantages. Although not proven by the present
study the authors assume that multimodal GIST-treatment, as performed in reference-centers, is
required for advanced or high risk disease. Our data suggest the potential for minimally invasive GIST
resection to achieving comparable oncological outcomes as after open surgery while providing low
morbidity rates.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.nna, Department of Surgery,
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Gastrointestinal stromal tumors (GISTs) are rare but represent
themost commonmesenchymal tumors of the digestive tract.8,9 An
incidence of 7e14 cases per 1 million general population per year
was reported.8 Since the discovery of the tyrosine kinase KIT as a
major pathogenetic factor in the development of these tumors,
GISTs were reclassiﬁed resulting in a 25-fold increase of GIST di-
agnoses.8 Today it is proven that GISTs originate from stem cells
with the potential to differentiate to the interstitial cell of Cajal, and. All rights reserved.
Table 1
Primary manifestations and diagnostics.
Variable n (%)
First symptoms
No data 39 (24.5)
Incidental ﬁnding 48 (30.2)
Unspeciﬁc. Upper GI-symptoms 25 (15.7)
Acute GI bleeding 11 (6.9)
Chron. GI bleeding 10 (6.3)
Dysphagia 2 (1.3)
GI Perforation 3 (1.9)
Stenosis/compression 4 (2.5)
Bleeding þ others 2 (1.3)
GI perforation þ others 1 (0.6)
Multiple symptoms 10 (6.3)
Other symptoms 4 (2.5)
Variable n (%) Variable n (%)
CT preoperative CT follow-up
No data 25 (15.7) No data 18 (11.3)
No CT 28 (17.6) No CT 31 (19.5)
CT 106 (66.7) CT 110 (69.2)
PET preoperative PET follow-up
No data 36 (22.6) No data 30 (18.9)
No PET 108 (67.9) No PET 84 (52.8)
PET 15 (9.4) PET 45 (28.3)
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ORIGINAL RESEARCHintestinal pacemaker cell.23 Underlying pathologicmechanism is an
activating mutation of the KIT-gene, rarer a PDGRFA-gene-mutation
followed by a constitutive activation of tyrosine kinase activity5
This represents the basic approach for targeted therapy with
tyrosine kinase inhibitors (TKI).15 The biological behavior of GISTs is
heterogenous and unpredictable.1,3 Risc classiﬁcations consider
mitotic rate, tumor size and localization.25
GISTs require resection for cure, and when tumor size rather
than tumor cell free surgical margins increase the survival time
local resection is the most important factor regarding overall
survival.14
Standard therapy of localized GISTs is surgical resection with
tumor free margins and intact tumor capsule.24
Since the development of minimally invasive surgical ap-
proaches there is an ongoing discussion regarding the role of
laparoscopic surgery in patients with GISTs. According to the Na-
tional Comprehensive Cancer Network (NCCN) Task Force Report of
2010 laparoscopic resection of GISTs (up to 5 cm) is an accepted
therapy strategy.7,16
Here we present our single-center experience with the treat-
ment of GISTs focusing on surgical approaches and techniques.
2. Methods and patients
All GIST-patients who underwent surgical treatment in our
institution between the years 1994 and 2011 were identiﬁed in a
database and were included into the analysis. Clinicopathohisto-
logical ﬁndings and data on therapy and outcome were reviewed
retrospectively.
2.1. Pathohistological deﬁnitions and risk classiﬁcations
GIST diagnosis was made by pathohistological, immunohisto-
chemical and mutation analyses following international guidelines
and standardized classiﬁcations, performed at the Clinical Institute
of Pathology, Medical University of Vienna. Tumors diagnosed prior
to the late 1990s retrospectively underwent reclassiﬁcation into the
“new” entity “GIST” by immunohistochemical staining and
sequencing analyses.
2.2. Deﬁnitions and outcome parameters
Resection type was categorized into organ preservative pro-
cedures and organ resection. Follow-up time was deﬁned as the
time period from ﬁrst diagnosis to the last follow-up visit or date of
death. Recurrence-free time (RFT) was deﬁned as time from diag-
nosis to either recurrence or in cases without relapse to last follow-
up visit, which was considered a censored event. Further, time to
recurrence (TTR) represents the period from surgery to recurrence.
Survival time (ST) represents the time from ﬁrst diagnosis to death
within the observation period. Overall survival (OS) was deﬁned as
the time between primary surgery and death from GIST. Survival
until follow-up and not-GIST-related-deaths were considered
censoring events. Progression-free survival (PFS) was deﬁned as the
time period from surgery to ﬁrst evidence of recurrence or pro-
gression of disease in synchronously metastasized cases,
respectively.
2.3. Statistical analysis
Statistical analysis and calculations were done using IBM SPSS
statistics 19 performing independent samples t-test and Kaplane
Meier survival analysis. A p-Value 0.05 was considered statisti-
cally signiﬁcant.3. Results
3.1. Patients
A total of 159 patients including 83males (52.2%) and 76 females
(47.8%) were diagnosed with GIST at a median age of 63.8 years
(range: 29.4e94) and were surgically treated at the Department of
Surgery, Medical University of Vienna between 1994 and 2011. One
third of all GISTs (30.2%, n ¼ 48) were incidental ﬁndings. The
stomach presented the most common primary site (n ¼ 106, 66.7%)
followed by the small bowel (n ¼ 29, 18.2%). Furthermore, eight
extragastrointestinal stromal tumors, EGISTs (5%), were diagnosed
while 1 patient (0.6%) suffered from a Gistosis peritonei of un-
known origin. The median tumor size was 4.5 cm (range: 1e35 cm)
and most GISTs were staged as TNM T2 (43.4%, n ¼ 69). At ﬁrst
diagnosis 141 patients (88.7%) presented with localized disease
while 8 individuals (5%) and another 10 (6.3%) suffered from locally
and systemically advanced disease, respectively (Tables 1 and 2).
3.2. Pathohistology
About half of all patients underwent preoperative biopsy
(n ¼ 78, 49.1%) and thereof in 66.7% (n ¼ 52) a GIST was diagnosed,
while in 12.8% (n ¼ 10) at the minimum a mesenchymal tumor
could be detected. The remaining histological ﬁndings were either
inconclusive (3.1%), negative (2.5%) or provided a diagnosis other
than GIST (1.9%). The deﬁnitive histological results most frequently
showed spindel cell type (64.8%, n ¼ 103) while mitoses varied
from 0 to 139 (median: 4) per 50 high power ﬁelds (HPF).
Expression of C-KIT and PDGFRA protein was detected immu-
nohistochemically using standard protocols. Sequencing analysis
for exons 9, 11, 13 and 1 of KIT and exons 12 and 18 of PDGFRA genes
was performed as described previously.18,21,22 (Table 2).
3.3. Treatment
Overall, nine patients (5.7%) were subjected to neoadjuvant
Imatinib therapy with the aim to reach organ preservation (n ¼ 8)
and one time due to the necessity of surgery delay in a patient with
acute coronary syndrome and ongoing anticoagulation after coro-
nary angiography to prevent tumor progression. Surgical approach
Table 2
Clinical and pathohistological data.
Variable n (%) Variable n (%) Variable n (%)
Site of primary gist KIT-genea PDGFRA-genea
Stomach 106 (66.7) No data 2 (1.3) No analysis 2 (1.3)
Cardia 3 (1.9) No mutation 52 (32.7) No data 2 (1.3)
Duodenum 6 (3.8) Ex.9 Mut. 8 (5) No mutation 97 (61)
Jejunum/ileum 29 (18.2) Ex.11 Mut. 87 (54.7) Ex.12 Mut. 4 (2.5)
Colon 3 (1.9) Ex.13 Mut. 1 (0.6) Ex.18 Mut. 35 (22)
Rectum 3 (1.9) Ex.17 Mut. 4 (2.5) Ex.12 þ 18 Mut. 1 (0.6)
EGIST (Mesentery/omentum) 5 (3.1) Ex.9 þ 11 Mut. 2 (1.3) Mut. þ Polym.: 2Exs. 1 (0.6)
EGIST (Retroperitoneum) 3 (1.9) Ex.11 þ 17 Mut. 2 (1.3) Ex.18 Polym. 17 (10.7)
Gistosis peritonei 1 (0.6) Ex.11 þ 13 Mut. 1 (0.6)
Miettinen Fletcher Morphology
None 21 (13.2) Very low risk 18 (11.3) No data 1 (0.6)
Very low risk 42 (26.4) Low risk 54 (34) Spindle cell 103 (64.8)
Low risk 28 (17.6) Intermediate risk 34 (21.4) Epithelioid 32 (20.1)
Moderate risk 22 (13.8) High risk 53 (33.3) Mixed type 23 (14.5)
High risk 34 (21.4)
Not classiﬁableb 12 (7.5)
TNM_T Mitotic rate Tumor Size (cm): Mean: 4.5 (1e35)
No data 2 (1.3) Low (5 M/50 HPF) 107 (67.3) No data 2 (1.3)
T1 (<¼2 cm) 23 (14.5) High (>5 M/50 HPF) 52 (32.7)
T2 (>2 cme5 cm) 69 (43.4) IHC_C-KITc
T3 (>5 cme10 cm) 40 (25.2) Neg. 23 (14.5)
T4 (>10 cm) 25 (15.7) Pos. 136 (85.5)
a Ex.: Exon; Mut.: Mutation; Polym.: Polymorphism.
b Due to localization not classiﬁable by Miettinen risk classiﬁcation.
c IHC: Immunohistochemical assays.
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113 patients (71.1%) while 6 conversions (3.8%; conversion
rate ¼ 13.04%) to open surgery had to be done. Operative time
varied from 35 to 510 (median: 150) minutes and was signiﬁcantly
reduced in laparoscopic settings and in organ preserving pro-
cedures compared to open surgery or organ resection (mean: 130.6
vs. 183.4; p ¼ 0.001 and 148.5 vs. 235.6 min; p ¼ 0.000). Mean
operative time in organ preserving operations was 148.5 min and
235.6 min in organ resection (p ¼ 0.000). The number of tumor
related surgical procedures per person varied with a maximum of 6
(0.6%, n ¼ 1) and a mean of 1.4 vs. 1.1 operations per individual in
patients who underwent open or laparoscopic approached ﬁrst
treatment, respectively. Organ preserving procedures were per-
formed laparoscopically in 35.5% (n ¼ 38) and open in 64.5%
(n¼ 69) while organ resections were doneminimally invasive in 5%
(n ¼ 2) and conventionally in 95% (n ¼ 38). Complete surgical
resection (R0) was reached in 88.3% involving 39 laparoscopically
(97.5%) and 92 (85.2%) open treated patients and further 5 (83.3%)
patients, who underwent conversion to open surgery, while data
were insufﬁcient in 5 patients (3.1%). 2.5% (n¼ 1) and 14.8% (n¼ 16)
of laparoscopically and open resected patients, further 16.7% (n¼ 1)
of conversion-group were incompletely resected. While 88.4% of
organ preserving procedures led to R0-resection, complete resec-
tion could only be achieved in 78% of organ resections.
Gastric GISTswere resected by open and laparoscopic approach in
61.3% (n¼ 65) and in 34.9% (n¼ 37),while in3.8% (n¼ 4) a conversion
to open was carried out. Non anatomic segmental gastric resection
was the most frequently performed surgery (69.8%, n ¼ 74) and sub-
total gastrectomies were performed in 12.3% (13). Total gastrectomy
had to be done in 6.6% (n¼ 7) including one patientwith coincidental
gastric cancer and another one suffering from “familiary Gistosis”
with multiple gastrointestinal tumors of the stomach.
Two esophageal resections with gastric pull up (1.9%) were
performed and while this was indicated by esophageal cancer in
one case, the other patient suffered from two GISTs at the EGJ and
the esophagus.
The remaining ten patients underwent cardia or fundus resec-
tion, remnant gastrectomy or another stomach surgery.Three patients suffered from rectal GISTs and were treated
either by conventional intersphincteric rectum extirpation, trans-
sphincteric rectum resection or in one case by rectum resection
after three months of neoadjuvant Imatinib therapy.
Operative procedures of duodenal GISTs included three
duodenal wall enucleations with sewing-over, two duodenal
segmental resections and one Whipple-procedure, all performed
with an open approach.
About one third (29.6%, n ¼ 47) of the study population
received any chemotherapy. Of all 38 patients (23.9% of total) who
were treated with Imatinib, 10.5% (n ¼ 4) underwent a neo-
adjuvant, 50% (n ¼ 19) an adjuvant and 13.2% (n ¼ 5) a palliative
therapy. 10 patients (26.3%) had an Imatinib therapy in combined
settings.
3.4. Outcome, follow-up and survival
3.4.1. Surgical outcome
Complications occurred in 20.1% (n ¼ 32), most frequent was
postoperative bleeding (5%, n ¼ 8) followed by wound infections
(3.8%, n ¼ 6) (Table 3). Complication rates of laparoscopic and open
surgery differed remarkably [7.5% (n ¼ 3) vs. 23% (n ¼ 26)]. Overall
mean length of hospital stay was 13.9  9.8 days and signiﬁcantly
reduced in minimally invasive procedures (mean: 8.3 days vs. 16.1
days; p ¼ 0.000) as it was in organ preserving procedures in
contrast to organ resections (12.5 days vs. 18.5 days; p ¼ 0.002).
According to Clavien-Dindo-classiﬁcation grade I, II, IIIa and IIIb
were found in 7, 5, 4 and 15 cases, whereas 128 patients did not
show any complications. Grade IV and V were not found in our
series. Acute re-operations had to be done in 15 patients (9.4%)
within the hospital duration. In four cases (2.5%) surgical hernia
repair was performed due to incisional hernias after hospital
discharge.
3.4.2. Follow-up and survival
16.4% (n ¼ 26) of patients with primary localized disease
relapsed while 71.1% (n ¼ 113) remained disease-free within
observance period. More frequently than isolated local recurrence
Table 3
Complications.
Variable n (%) n (%) n (%) n (%)
Complications Overall Open Laparoscopic Conversion
None 120 (75.5) 81 (71.7) 36 (90) 3 (50)
Complication(s) 32 (20.1) 26 (23) 3 (7.5) 3 (50)
No data 7 (4.4) 6 (5.3) 1 (2.5)
Complication type
Wound infection/healing
deﬁcit
6 (3.8) 3 (2.7) 1 (2.5) 2 (33.3)
Thrombosis 1 (0.6) 1 (0.9) 0 (0)
Non-surg. complications 2 (1.3) 2 (1.8) 0 (0)
Wound healing deﬁcit þ
Hernia cicatricea
3 (1.9) 3 (2.7) 0 (0)
No data 6 (5.3) 1 (2.5)
Hernia cicatricea 3 (1.9) 2 (1.8) 0 (0) 1 (16.7)
Bleeding 8 (5) 7 (6.2) 1 (2.5)
Anastomotic leak 2 (1.3) 2 (1.8) 0 (0)
Anastomotic stenosis 2 (1.3) 1 (0.9) 1 (2.5)
Ileus 2 (1.3) 2 (1.8) 0 (0)
Bile-/pancreas-/stomach
wall ﬁstula
3 (1.9) 3 (2.7) 0 (0)
Resection type Organ preserving Organ resection No data
No complication 86 (76.8) 31 (75.6)
Complication(s) 22 (19.6) 9 (22)
No data 4 (3.6) 1 (2.4) 6 (100)
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registered, involving the liver in the majority of cases (Table 4).
66.7% (n ¼ 12) of all synchronously metastasized patients pro-
gressed, whereas ﬁve persons (27.8%), of whom 60% (n ¼ 3)
received a TKI-treatment, presented a stable disease within the
follow-up period. As consequence of relapse or progression,
another resection was performed in 17 cases (10.7%) of primary
limited diseases and in 4 initially advanced patients (2.5%).Table 4
Recurrences.
Variable n (%)
Any recurrence ever
None 113 (71.1)
Recurrence 26 (16.4)
Prim. locally advanced 8 (5)
Prim. systemic disease 10 (6.3)
No data 2 (1.3)
Recurrence localization
None 113 (71.1)
Local recurrence 6 (3.8)
Liver 6 (3.8)
Lung 1 (0.6)
Lung þ Liver 1 (0.6)
Generalization 1 (0.6)
Local þ Peritoneum 3 (1.9)
Local þ Liver 1 (0.6)
Local þ Other sides 6 (3.8)
Local þ Lung þ Liver 1 (0.6)
Prim. advanced þ Local recurrence 2 (1.3)
Prim. advanced þ Progression/recurrence 10 (6.3)
Prim. advanced, no progression/recurrence 6 (3.8)
No data 2 (1.3)
Med. Tx: 1st Recurrence/progression
No recurrence 113 (71.1)
Imatinib 14 (8.8)
Sunitinib 1 (0.6)
Non-TKI 3 (1.9)
Prim. advanced, no progression 5 (3.1)
Prim. advanced þ Progression þ Other CTX 6 (3.7)
Prim. advanced þ Progression þ Imatinib 5 (3.1)
No data 12 (7.5)
Tx: Therapy, CTX: Chemotherapy.Within a mean follow-up time of 5  4.2 years we registered a
mean recurrence-free time of 4 3.6 years, while the mean time to
recurrence, including the 26 patients who relapsed, was 1.7  1.6
years.
Forty patients (25.2%) died during observation time, whereas in
4 cases (2.5%) no survival data were available. 18 patients died from
GIST (11.3%), another 18 died from another cause and in 4 cases
(2.5%) the underlying reason of death was not detectable.
Nine (6.6%) completely resected and eight (44.4%) incompletely
resected patients died as consequence of the malignancy. Further-
more, the mean survival time was 5.1 years and 2.6 years of
completely and incompletely resected patients, respectively.
No minimally invasive operated patients died from GIST,
whereas 15.9% (n ¼ 18) of conventionally treated persons died a
GIST-related death while observed.
We registered a mean survival time of 3.7  2.7 years, a mean
progression-free survival time of 3.6 3.7 years and a mean overall
survival of 4.5  3.8 years (Table 5).4. Discussion
Depending on tumor’s size and site surgical GIST-treatment
spans a wide spectrum from quite simple to very challenging.
However, surgery represents the only chance for cure and local
resection is the most important factor regarding OS in localized
resectable GISTs.6,14
To ensure adequate surgical GIST resection tumor rupture and
spillage should be avoided at all costs by using a “no touch”-tech-
nique to preserve the tumor’s capsule. Otherwise tumor cells may
disseminate into the abdominal cavity leading to peritoneal seed-
ing. Furthermore, complete histological resection has to be the
primary aim. Wide margins due to extensive resection usually are
not necessary and do not improve outcome.3,9,16,19 In general,Variable n (%)
Progression in prim. advanced patients
No data 1 (0.6)
No progression/recurrence 5 (3.1)
Progression/recurrence 12 (7.5)
Not prim. advanced 141 (88.7)
Metachron. Metastases
None 115 (72.3)
Liver 10 (6.3)
Lung 3 (1.9)
Peritoneum 5 (3.1)
Liver þ Lung 2 (1.3)
Liver þ Peritoneum 1 (0.6)
Others 1 (0.6)
Prim. advanced þ Progression 12 (7.5)
Sec. Generalization 1 (0.6)
Prim. advanced, no progression 5 (3.1)
No data 4 (2.5)
Surg. Tx: 1st Recurrence/progression
No recurrence 113 (71.1)
Surgery 17 (10.7)
No surgery 8 (5)
Prim. advanced, no progression 6 (3.8)
Prim. advanced þ Progression þ Surgery 4 (2.5)
Prim. advanced þ Progression, no surgery 8 (5)
No data 3 (1.9)
Table 5
Outcome.
Variable n (%) n (%) n (%)
Latest status Organ preserving Organ resection No data
Dead (any cause) 23 (20.5) 15 (36.6)
Alive 86 (76.8) 25 (61)
No data 3 (2.7) 1 (2.4) 6 (100)
GIST-related death 9 (8) 9 (26.5)
CTX (any) Never CTX CTX received No data
Dead (any cause) 17 (16.5) 19 (40.4)
Alive 85 (82.5) 26 (55.3)
No data 1 (1) 2 (4.3) 9 (100)
GIST-related death 0 (0) 15 (31.9)
Imatinib adjuvant Not received Received No data
Dead (any cause) 26 (21.1) 11 (37.9)
Alive 95 (77.2) 17 (58.6)
No data 2 (1.6) 1 (3.4) 7 (100)
GIST-related death 7 (5.7) 9 (31)
Imatinib (any setting) Never Imatinib No data
Dead (any cause) 24 (21.1) 13 (34.2)
Alive 89 (78.1) 23 (60.5)
No data 1 (0.9) 2 (5.3) 7 (100)
GIST-related death 7 (6.1) 9 (23.7)
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spread in sporadic, non hereditary GISTs.2,6,12
We found lymph node metastases in two patients (1.3%) but
they did not fulﬁll the criteria for “pediatric-type” GISTs (i.e. lack of
KIT and PDGFRA mutations, mixed spindle cell/epitheloid
morphology, multifocal/multinodal growth, gastric localization)18
and both died from this malignancy.
Several studies have reported about the feasibility of minimally
invasive GIST resection and recommended its use for various tumor
size limits and locations. Recommendations of the GIST consensus
conference 2004 described laparoscopic approach as acceptable for
only small GIST (<2 cm) due to concerns of tumor rupture or
spillage.19
Due to centralization of GIST-treatment to high-volume centers
and improvements of laparoscopic skills within the past decade
have resulted in reports of signiﬁcant enhancements regarding
postoperative morbidity and survival, partially resulting from
increased complete resection rates.10,16,19,20
As scheduled minimally invasive surgery minimizes patient
morbidity without declining the oncological outcome measured by
R0-rates and relapse rates.4,13,19
Our initial experience with gastric GIST resection has been
published by Silberhumer 2009 presenting 22 laparoscopically
treated patients with a mean tumor diameter of 3.5  1.4 cm.
Including the four conversions a complete resection rate of 100%
could be achieved.20
In our series minimally invasive procedures signiﬁcantly
reduced operative time, length of hospitalization and postoperative
morbidity. Laparoscopic performance reduced complications from
23% (n ¼ 26) after open surgery to 7.5% (n ¼ 3). However, mean
tumor diameter was higher in open than in laparoscopically treated
patients (7 cm vs. 4 cm).
Regarding complication types anastomotic leaks were found
only after conventional procedures (1.8%, n ¼ 2), while anastomotic
stenosis was registered after laparoscopic (2.5%, n ¼ 1) and open
(0.9%, n ¼ 1) surgery. It is to note that the majority of lapa-
roscopically treated patients received an atypical gastric resection.
Our data analogical to literature demonstrate that complete
resection is most important for outcome and survival as only 6.6%
(n ¼ 9) of all complete resected patients (n ¼ 136) died from GIST
within the observance time compared to 44.4% (n¼ 8) of incomplete
resected (n ¼ 18). Mean survival time was 5.1 years and 2.6 years of
completely and incompletely resected patients, respectively. In ourseries laparoscopic procedures led to a higher R0-rate (97.5%) than
open surgery (85.2%).
Although the necessity of oncological radicality is proven the
preferred approach and resection type is still not well
established.1,10,14
Neoadjuvant use of Imatinib is associated with decreased
tumor-volume resulting in increased R0-rates in locally advanced
GIST.11 Long term Imatinib treatment of advanced or relapsed GIST
has been reported to be safe and prolongs survival time.17
Within the last years TKI use in GIST-treatment expanded
constantly. Even so dosage and duration of neoadjuvant therapy as
well as optimal time for surgery remains a matter of discussion.
However, since postoperative relapse rates are up to 90% in primary
localized GISTs multimodal treatment is required urgently.
Due to increasing surgical experience and technical advance-
ments, minimally invasive approaches can be applied to tumors of
larger size and difﬁcult sites within clinical trials without
compromising oncological outcomes.
We recognize the limited validity of this not pair-matched study
but our results suggest that minimally invasive surgery can lead to
comparable oncological outcome as open procedures while
decreasing operative time, length of hospital stay and postoperative
morbidity. Randomized trials dealing with this issue are necessary.
5. Conclusion
Complete surgical resection is the most important factor with
respect to survival regardless of surgical approach or technique.
Laparoscopic GIST resection, providing right indications and per-
formance by an experienced surgeon is safe, feasible, has low
morbidity rates and achieves equal oncological outcomes as
reached by open surgery. Since laparoscopic skills and experience
in GIST resection and oncological knowledge inﬂuence patient
outcome the authors assume, although not proven by the present
study, that GIST clariﬁcation and treatment should be performed in
a reference center where, based on decisions of interdisciplinary
tumorboards, multimodal therapeutic strategies are ensured.
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